trial

Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

NCTId NCT01006551
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 40 (actual)
Sponsored by University of North Carolina, Chapel Hill
Primary completion 2006-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2002-12
Primary completion
2006-02
Eligibility
ALL · 6 Years · 19 Years

Interventions & indications

Drugs
Ziprasidone

Sponsors

University of North Carolina, Chapel HillLead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Collaborator
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Linmarie Sikich, MDPrincipal Investigator

Sites

4 total
Medford, United StatesChapel Hill, United StatesCleveland, United StatesSeattle, United States

Linked catalysts

1
Ziprasidone in Early Onset Schizophrenia Spectrum Disorders — primary completion2006-02

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE2
Primary Completion Date
2006-02
Status
COMPLETED
relationships
The graph out of here
drug
Ziprasidone
drug
lead_sponsor
University of North Carolina, Chapel Hill
company
collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Linmarie Sikich, MD
person